uploads///Graph

Endo International’s Earnings Projections for 2018

By

Updated

EPS projections for 2018

On its third-quarter earnings conference call, Endo International (ENDP) raised its adjusted diluted EPS guidance for 2018 from its previously projected range of $2.50–$2.60 to $2.65–$2.75. The company has also raised its adjusted EBITDA guidance for 2018 from the previously projected range of $1.27 billion–$1.33 billion to $1.32 billion–$1.34 billion.

Wall Street analysts expect Endo International to report adjusted diluted EPS of $2.70, a YoY fall of 29.68%, in 2018. The company is expected to witness adjusted diluted EPS of $2.71, a YoY rise of 0.47%, in 2019. Wall Street analysts also expect Endo International to report adjusted diluted EPS of $2.96, a YoY rise of 8.99%, in 2020.

Analysts expect Endo International’s adjusted diluted EPS to be close to $0.60, a YoY fall of 22.64%, in the fourth quarter.

Article continues below advertisement

Margin guidance

Endo International has revised its adjusted gross margin guidance for 2018 from the previously projected range of 68.5%–69.5% to 68.5%. As per its third-quarter earnings conference call, although new products—such as the authorized generic versions of INVANZ and Colcrys—launched in July have raised Endo International’s 2018 revenue outlook, they’re expected to witness lower adjusted gross margins in the second half of 2018. The change in product mix has resulted in a slight downward revision of the company’s gross margin guidance.

Wall Street analysts expect Endo International to report an adjusted gross margin of 68.65%, a YoY expansion of 565 basis points, in 2018. The company is expected to have an adjusted gross margin of 68.40%, a YoY contraction of 25 basis points, in 2019. Wall Street analysts also expect Endo International to report an adjusted gross margin of 68.86%, a YoY expansion of 8.99%, in 2020.

In the next article, we will discuss Endo International’s earnings projections for 2018.

Advertisement

More From Market Realist